4 Hematology Headlines You Missed in April 2026

April 2026 brought major developments in hematology, particularly in sickle cell disease (SCD), with advances spanning phase 3 therapeutics, gene-editing strategies, pediatric thrombosis prevention, and global disparities research.

From promising efficacy data for etavopivat and renizgamglogene autogedtemcel (reni-cel) to new anticoagulant prophylaxis guidance for pediatric venous thromboembolism (VTE), the month’s headlines highlighted both innovation and persistent unmet needs across hematologic care.